Autologous Bone Marrow-derived Mesenchymal Stem Cells for Atrophic Endometrium in Patients With Repeated IVF Failures

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

March 16, 2019

Study Completion Date

December 28, 2019

Conditions
Infertility, FemaleInfertility of Uterine OriginAsherman Syndrome
Interventions
BIOLOGICAL

bone marrow-derived MSC and HRT

"* Transplantation procedure to endometrial cavity is performed with ultrasound guidance on menstrual cycle day 5-6 through uterine cervix using cater for embryo transfer with 1 ml of suspension containing 5 millions of autologous bone marrow-derived mesenchymal stem cells~* Three cycles of HRT following MSC transplantation;~* Pipelle-biopsy of endometrium on day 20 of hormonal replacement therapy of the last (third) cycle;~* Frozen/thawed embryo transfer 3-6 months after transplantation."

OTHER

hormonal replacement therapy

"standard treatment of hypoplastic endometrium or Asherman's syndrome:~* Three cycles of HRT preceding frozen/thawed embryo transfer;~* Frozen/thawed embryo transfer."

Trial Locations (1)

199034

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology, Saint Petersburg

All Listed Sponsors
lead

D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

OTHER

NCT03166189 - Autologous Bone Marrow-derived Mesenchymal Stem Cells for Atrophic Endometrium in Patients With Repeated IVF Failures | Biotech Hunter | Biotech Hunter